曹磊;任华;

• 1:中国医学科学院北京协和医学院北京协和医院胸外科

摘要(Abstract)：

<正>肺癌是严重威胁人类生命健康的主要疾病之一,也是癌症死亡的主要原因[1]。尽管人类尝试了多种治疗肺癌的方法,但效果非常不理想而且不良反应较多。因此,迫切需要寻找一种新的既能提高疗效又具有较少不良反应的肺癌治疗方法。免疫学治疗作为新

关键词(KeyWords)： 肺癌;免疫治疗;肿瘤疫苗

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 曹磊;任华;

参考文献(References)：

• [1]Jemal A,Siegel R,Xu J,etal.Cancer statistics,2010[J].CA Cancer J Clin,2010,60:277-300.
• [2]Isobe T,Herbst RS,Onn A.Current management of ad-vanced non-small cell lung cancer:targeted therapy[J].Semin Oncol,2005,32:315-328.
• [3]Giaccone G.Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer[J].J Clin On-col,2005,23:3235-3242.
• [4]Hsu JY,Wakelee HA.Monoclonal antibodies targeting vas-cular endothelial growth factor:current status and future challenges in cancer therapy[J].BioDrugs,2009,23:289-304.
• [5]Kakimi K,Nakajima J,Wada H.Active specific immuno-therapy and cell-transfer therapy for the treatment of non-small cell lung cancer[J].Lung Cancer,2009,65:1-8.
• [6]Raez LE,Fein S,Podack ER.Lung cancer immunotherapy[J].Clin Med Res,2005,3:221-228.
• [7]Novellino L,Castelli C,Parmiani G.A listing of human tumor antigens recognized by T cells:March2004update[J].Cancer Immunol Immunother,2005,54:187-207.
• [8]Pardoll D.Does the immune system see tumors as foreign or self[J].Annu Rev Immunol,2003,21:807-839.
• [9]Hirschowitz EA,Hiestand DM,Yannelli JR.Vaccines for lung cancer[J].J Thorac Oncol,2006,1:93-104.
• [10]Palma M,Choudhury A,Mellstedt H.Cancer vaccines fornon-small-cell lung cancer[J].Minerva Chir,2009,64:643-653.
• [11]Dredge K,Marriott JB,Todryk SM,et al.Adjuvants and the promotion of Th1-type cytokines in tumour immunothera-py[J].Cancer Immunol Immunother,2002,51:521-531.
• [12]Pashine A,Valiante NM,Ulmer JB.Targeting the innate immune response with improved vaccine adjuvants[J].Nat Med,2005,11:S63-S68.
• [13]Smyth MJ,Cretney E,Kershaw MH,et al.Cytokines in cancer immunity and immunotherapy[J].Immunol Rev,2004,202:275-293.
• [14]CranmerLD,TrevorKT,Hersh EM.Clinical applications of dendritic cell vaccination in the treatment of cancer[J].Cancer Immunol Immunother,2004,53:275-306.
• [15]Sandler AB,Dubinett SM.COX-2inhibition and lung canc-er[J].Semin Oncol,2004,3:45-52.
• [16]Bartlett JB,Dredge K,Dalgleish AG.The evolution of tha-lidomide and its IMiD derivatives as anticancer agents[J].Nat Rev Cancer,2004,4:314-322.
• [17]Cross D,Burmester JK.Gene therapy for cancer treatment:past,present and future[J].Clin Med Res,2006,4:218-227.
• [18]Kimura H,Yamaguchi Y.A phase III randomized study of interleukin-2lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma[J].Canc-er,1997,80:42-49.
• [19]Kimura H,Iizasa T,Ishikawa A,etal.Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tis-sue culture of tumor-draining lymph nodes in primary lung cancer patients[J].Anticancer Res,2008,28(2B):1229-1238.
• [20]Garc Garcia B,Neninger E,de la Torre A,et al.Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor anti-bodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine[J].Clin Cancer Res,2008,14:840-846.
• [21]Neninger Vinageras E,de la Torre A,Osorio Rodriguez M,et al.Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer[J].J Clin Oncol,2008,26:1452-1458.
• [22]Butts C,Murray N,Maksymiuk A,et al.Randomized phase IIB trial of BLP25liposome vaccine in stage IIIB and IV non-small-cell lung cancer[J].J Clin Oncol,2005,23:6674-6681.
• [23]Butts C,Murray RN,Smith CJ,et al.A multicenter open-label study to assess the safety of a newformulation of BLP25liposome vaccine in patients with unresectable stage III non-small-cell lung cancer[J].Clin Lung Cancer,2010,11:391-395.
• [24]Ramlau R,Westeel V,Papai Z,et al.Randomized phase IIb trial evaluating the therapeutic vaccine TG4010(MVA-MUC1-IL2)as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer(NSCLC)[J].J Tho-rac Oncol.2008,3:735-744.
• [25]Shigematsu Y,Hanagiri T,Shiota H,et al.Clinical signifi-cance of cancer/testis antigens expression in patients with non-small cell lung cancer[J].Lung Cancer,2010,68:105-110.
• [26]Vansteenkiste J,Zielinski M,Linder A,et al.Final results of a multi-center,double-blind,randomized,placebo-con-trolled phase II study to assess the efficacy of MAGE-A3im-munotherapeutic as adjuvanttherapy in stage IB/II non-small cell lung cancer(NSCLC)[J].J Clin Oncol,2007,25(18s):7554.
• [27]Atanackovic D,Altorki NK,Cao Y,et al.Booster vaccina-tion of cancer patients with MAGE-A3protein reveals long-term immunological memory or tolerance depending on prim-ing[J].Proc Natl Acad Sci USA,2008,105:1650-1655.
• [28]Dranoff G,Jaffee E,Lazenby A,et al.Vaccination with ir-radiated tumor cells engineered to secrete murine granulo-cyte-macrophage colonystimulating factor stimulates potent,specific,and long-lasting anti-tumor immunity[J].Proc Natl Acad Sci USA,1993,90:3539-3543.
• [29]Salgia R,Lynch T,Skarin A,etal.Vaccination with irradi-ated autologous tumor cells engineered to secrete granulo-cyte-macrophage colonystimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma[J].J Clin Oncol,2003,21:624-630.
• [30]Correale P,Miano ST,Remondo C,et al.Second-line treatment of non small cell lung cancer by biweekly gemcit-abine and docetaxel+/-granulocyte-macrophage colony stimulating factor and lowdose aldesleukine[J].Cancer Bi-ol Ther,2009;8:497-502.
• [31]Nemunaitis J,Sterman D,Jablons D,et al.Granulocyte-macrophage colony-stimulating factor gene-modified autolo-gous tumor vaccines in non-small-cell lung cancer[J].J Natl Cancer Inst,2004,96:326-333.
• [32]Nemunaitis J,Jahan T,Ross H,et al.Phase1/2trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer[J].Cancer Gene Ther,2006,13:555-562.
• [33]Kong F,Jirtle RL,Huang DH,et al.Plasma transforming growth factor-beta1level before radiotherapy correlates with long term outcome of patients with lung carcinoma[J].Cancer1999,86:1712-1719.
• [34]Nemunaitis J,Dillman RO,Schwarzenberger PO,et al.Phase II study of belagenpumatucel-L,a transforming growth factor beta-2antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer[J].J Clin Oncol,2006,24:4721-4730.
• [35]Nemunaitis J,Nemunaitis M,Senzer N,etal.Phase II trial of Belagenpumatucel-L,a TGF-beta2antisense gene modi-fied allogeneic tumorvaccine in advanced non small cell lung cancer(NSCLC)patients[J].Cancer Gene Ther,2009,16:620-624.